The firm, which provides laboratory and contract research services to the drug industry, will consult the board on issues ranging from the personalised medicines market to the emerging field of biomarker assay development.
The board is made up of: John Bloom, President, Bloom Consulting Services; Ronald Gingerich, President, Conturix Research; and Thomas Lohmann, Director of Clinical Pathology, Baylor Healthcare System and CMO, Med Fusion Clin-Labs and Clin-Trials.
PBI CEO Ron Helm said that: “We are seeing profound changes in the pharma and biotech industries and in the general healthcare landscape. These changes include a shift toward personalized medicine and an expectation that novel drugs will be highly targeted, effective, and safe.
“These developments present both challenges and opportunities, which we believe PBI is uniquely positioned to exploit. We believe our SAB has the knowledge, experience and insight to advise us as we continue to refine our technology strategy in the evolving drug-development marketplace."
In addition to the new SAB Pacific said it will seek to capitalize on current market opportunities by evaluating strategies for expansion of services and activities by organic growth as well as by external partnerships or other strategic initiatives.
More to follow